Skip to main navigation

Skip to content

Careers
Contact Us

Home
About
Research & Development
Therapies
Newsroom
Investors

Careers
Contact Us

Press Releases

Overview
Press Releases
Events and Presentations
- Annual General Meeting
Corporate Governance
Stock Information
Financials
- SEC Filings
- Earnings Releases
Resources
- Email Alerts
- Contact IR

Year

Oct 01, 2026

Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma

Sep 25, 2026

Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion

Sep 15, 2026

Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

Sep 10, 2026

Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting

Sep 01, 2026

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

Aug 11, 2026

Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights

Jul 28, 2026

Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results

Jul 27, 2026

Legend Biotech Announces CEO Transition

Jun 17, 2026

Legend Biotech Corporation Announces Pricing of Public Offering

Jun 17, 2026

Legend Biotech Corporation Announces Proposed Public Offering

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 21

GLOBAL HEADQUARTERS

2101 COTTONTAIL LANE

SOMERSET, NJ 08873, USA

+1-732-317-5050

Footer Links

ABOUT US
RESEARCH & DEVELOPMENT
THERAPIES
NEWSROOM
CAREERS
ETHICS & COMPLIANCE
COMPLIANCE HOTLINE
INVESTORS
COOKIE POLICY
PRIVACY NOTICE
LEGAL NOTICE
CONTACT US
SITE MAP

© 2026 Legend Biotech. All rights reserved. dedication

You are about to leave Investors.LegendBiotech.com